| Medical Mutual | Vyepti® (eptinezumab-jjmr) (Intravenous) | 2026-07-01 |
| Medical Mutual | Enhanced Oncology Value: Vyjuvek® (beremagene geperpavec-svdt) (Topical) (EOV) | 2026-07-01 |
| Medical Mutual | Oncology Value: Zevaskyn® (prademagene zamikeracel) (Topical) | 2026-07-01 |
| Medical Mutual | Oncology Value: Zynyz® (retifanlimab-dlwr) (Intravenous) | 2026-07-01 |
| Anthem Blue Cross | Electric Tumor Treatment Field (TTF) Therapy | 2026-07-01 |
| Anthem Blue Cross | Intraluminal Left Atrial Appendage Closure Devices | 2026-07-01 |
| Anthem Blue Cross | Standard Lipid Panel Testing | 2026-07-01 |
| BCBS Florida Coverage Guidelines | Remibrutinib (Rhapsido) Tablet (09-J5000-36) | 2026-07-01 |
| Ambetter Health Iowa Clinical | Trigger Point Injections for Pain Management | 2026-07-01 |
| UHC Medicaid Medical & Drug | Adakveo® (Crizanlizumab-Tmca) – Community Plan Medical Benefit Drug Policy | 2026-07-01 |